Device Trial Radar · NCT03015649
Long Term Use of SAVI SCOUT: Pilot Study
Last checked: Nov 19, 2026Latest source record: May 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Feb 3, 2017
Primary completion
Sep 10, 2018
Study completion Apr 4, 2019
Sponsor
- Lead sponsor
- Envision Healthcare Scientific Intelligence, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cianna Medical, Inc.
- First posted
- Jan 10, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the performance of FDA-cleared SAVI SCOUT Breast Localization and Surgical Guidance System (SCOUT) over a longer duration prior to surgery. The device is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue. The SCOUT device standard of care use is placement up to 30 days prior to surgery to assist surgeons in the localization and retrieval of breast/axillary lesions. Routine image-guided methods (Mammography, Ultrasound, and CT) are used. In this study, investigators will assess the longer term placement of the SCOUT device over an extended time (31 - 365 days) in order to address the needs of patients who require neoadjuvant treatment prior to definitive surgery.
Conditions
- Breast Diseases
Interventions
SAVI SCOUT Surgical Guidance SystemDevice
SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Considered to Have a Successful SurgeryTime frame: 31 - 365 days prior to surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Envision Physician Scientific Research, Inc. formerly Sheridan Healthcare, Inc.
Plantation, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.